Prevention and treatment of acute GvHD

C. Messina, M. Faraci, V. de Fazio, G. Dini, M. P. Calò, E. Calore

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids. Moreover, while the absence of acute GvHD (aGvHD) is associated with a higher risk of relapse of the underlying malignant disease, severe aGvHD usually induces the occurrence of life-threatening complications such as severe infections. This article summarizes the current state of aGvHD prophylaxis and treatment.

Original languageEnglish
JournalBone Marrow Transplantation
Volume41
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Acute Disease
Stem Cells
Therapeutics
Steroids
Morbidity
Transplants
Recurrence
Mortality
Infection
Transplant Recipients

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Messina, C., Faraci, M., de Fazio, V., Dini, G., Calò, M. P., & Calore, E. (2008). Prevention and treatment of acute GvHD. Bone Marrow Transplantation, 41(SUPPL. 2). https://doi.org/10.1038/bmt.2008.57

Prevention and treatment of acute GvHD. / Messina, C.; Faraci, M.; de Fazio, V.; Dini, G.; Calò, M. P.; Calore, E.

In: Bone Marrow Transplantation, Vol. 41, No. SUPPL. 2, 06.2008.

Research output: Contribution to journalArticle

Messina, C, Faraci, M, de Fazio, V, Dini, G, Calò, MP & Calore, E 2008, 'Prevention and treatment of acute GvHD', Bone Marrow Transplantation, vol. 41, no. SUPPL. 2. https://doi.org/10.1038/bmt.2008.57
Messina C, Faraci M, de Fazio V, Dini G, Calò MP, Calore E. Prevention and treatment of acute GvHD. Bone Marrow Transplantation. 2008 Jun;41(SUPPL. 2). https://doi.org/10.1038/bmt.2008.57
Messina, C. ; Faraci, M. ; de Fazio, V. ; Dini, G. ; Calò, M. P. ; Calore, E. / Prevention and treatment of acute GvHD. In: Bone Marrow Transplantation. 2008 ; Vol. 41, No. SUPPL. 2.
@article{3cf60fe82640451c88198da1b738c5fd,
title = "Prevention and treatment of acute GvHD",
abstract = "GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids. Moreover, while the absence of acute GvHD (aGvHD) is associated with a higher risk of relapse of the underlying malignant disease, severe aGvHD usually induces the occurrence of life-threatening complications such as severe infections. This article summarizes the current state of aGvHD prophylaxis and treatment.",
author = "C. Messina and M. Faraci and {de Fazio}, V. and G. Dini and Cal{\`o}, {M. P.} and E. Calore",
year = "2008",
month = "6",
doi = "10.1038/bmt.2008.57",
language = "English",
volume = "41",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Prevention and treatment of acute GvHD

AU - Messina, C.

AU - Faraci, M.

AU - de Fazio, V.

AU - Dini, G.

AU - Calò, M. P.

AU - Calore, E.

PY - 2008/6

Y1 - 2008/6

N2 - GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids. Moreover, while the absence of acute GvHD (aGvHD) is associated with a higher risk of relapse of the underlying malignant disease, severe aGvHD usually induces the occurrence of life-threatening complications such as severe infections. This article summarizes the current state of aGvHD prophylaxis and treatment.

AB - GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids. Moreover, while the absence of acute GvHD (aGvHD) is associated with a higher risk of relapse of the underlying malignant disease, severe aGvHD usually induces the occurrence of life-threatening complications such as severe infections. This article summarizes the current state of aGvHD prophylaxis and treatment.

UR - http://www.scopus.com/inward/record.url?scp=45749117691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749117691&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.57

DO - 10.1038/bmt.2008.57

M3 - Article

VL - 41

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 2

ER -